Last reviewed · How we verify
Lemborexant tablets
Treats insomnia by modulating orexin receptors
Treats insomnia by modulating orexin receptors Used for Insomnia.
At a glance
| Generic name | Lemborexant tablets |
|---|---|
| Also known as | E2006 |
| Sponsor | Shanghai Mental Health Center |
| Drug class | Orexin receptor antagonist |
| Target | Orexin receptor |
| Modality | Small molecule |
| Therapeutic area | Neurology |
| Phase | Phase 2 |
Mechanism of action
Lemborexant is a dual orexin receptor antagonist that has been shown to improve sleep quality and reduce symptoms of insomnia.
Approved indications
- Insomnia
Common side effects
- Headache
- Nausea
- Dizziness
Key clinical trials
- Lemborexant in Delayed Sleep Phase Syndrome (PHASE4)
- A Multicenter Observational Study of Lemborexant on Insomnia Patients With Psychiatric Disorders
- Lemborexant for Sleep and Delirium Prevention in Elderly ICU Patients (PHASE4)
- Lemborexant Shift Work Treatment Study (PHASE4)
- A Dual Orexin Receptor Antagonist to Reduce Biomarkers of Neurodegeneration in Adults With Insomnia. (PHASE2)
- Effects of Lemborexant as a Treatment for Moderate-to-severe OSA Patients With Low Arousal Threshold (PHASE1, PHASE2)
- The Effects of Lemborexant on the Ability to Sleep During Daytime (PHASE2)
- A Study to Assess the Pharmacodynamics of Lemborexant in Korean Participants With Insomnia Disorder (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Lemborexant tablets CI brief — competitive landscape report
- Lemborexant tablets updates RSS · CI watch RSS
- Shanghai Mental Health Center portfolio CI